Loading…
Employees: 7,906
Size Hygeia Healthcare (6078.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $861M, the 631st largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$10.99 on 6 Nov 2026.
Performance Over six months the shares fell 7.1%, against -11.9% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 1.6% over the last twelve months (peer median +2.8%); the operating margin is 14.2% (peer median 8.9%).
Valuation It trades at 11.0× forward earnings against a peer median of 27.2× (3rd cheapest of 8).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.3 points below its cost of capital (8.7% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$4.45B | HK$4.35B | HK$4.82B | HK$4.50B | HK$3.72B |
| Revenue growth | — | -10% | +7% | +21% | — |
| Gross profit | HK$1.15B | HK$1.11B | HK$1.34B | HK$1.34B | HK$1.14B |
| EBITDA | HK$969M | HK$930M | HK$1.23B | HK$1.14B | HK$999M |
| Net income | HK$203M | HK$178M | HK$649M | HK$755M | HK$554M |
| Free cash flow | HK$540M | HK$424M | HK$12.2M | -HK$246M | HK$44.0M |
| Capital expenditure | HK$455M | HK$524M | HK$667M | HK$1.04B | HK$706M |
| Total debt | n/a | HK$2.72B | HK$2.97B | HK$3.00B | HK$1.45B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6078.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.7% | -8.6% | 2nd highest of 21 |
| 6-month return | -7.1% | -11.9% | 5th highest of 20 |
| Distance from 52-week high | -24.5% | -37.2% | 3rd highest of 21 |
| Revenue growth (TTM) | +1.6% | +2.8% | 7th lowest of 18 |
| Operating margin | 14.2% | 8.9% | 6th highest of 18 |
| Forward P/E | 11.0× | 27.2× | 3rd cheapest of 8 |
| Growth the price implies (Req g, 7 yrs) | 4.8% | 6.6% | 5th least demanding of 9 |
| Growth delivered (Del g) | +22.5% | +2.3% | 3rd highest of 9 |
| Hurdle (Req g minus delivered) | -17.7 pp | -5.0 pp | least demanding of 9 |
| ROIC minus cost of capital | -3.3 pp | -1.9 pp | 7th lowest of 18 |
| EV / EBITDA | 8.8× | 18.2× | 3rd cheapest of 7 |
| Net debt / EBITDA | 1.8× | -0.6× | 2nd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hygeia Healthcare 6078.HK | Hong Kong | $861M | -7% | +2% | 14% | 11.0× | 4.8% | +22.5% |
| Kaken Pharmaceutical 4521.T | Japan | $854M | -8% | -7% | 11% | 24.5× | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $874M | -2% | +2% | 9% | 41.4× | 2.5% | +12.4% |
| Daewoong Pharm 069620.KS | South Korea | $874M | -30% | +9% | 12% | 5.8× | n/a | n/a |
| Aktis Oncology AKTS | United States | $880M | -15% | +337% | -1,150% | n/a | n/a | n/a |
| Luye Pharma 2186.HK | Hong Kong | $839M | -36% | +3% | 18% | 8.1× | -10.5% | +1.9% |
| Corvus Pharmaceuticals CRVS | United States | $887M | -32% | n/a | n/a | n/a | n/a | n/a |
| Latigo Biotherapeutics LTGO | United States | $835M | n/a | n/a | n/a | n/a | n/a | n/a |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $835M | -28% | +23% | 36% | 27.2× | 17.1% | +22.7% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $892M | +19% | +13% | 18% | n/a | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $893M | -27% | +1% | 0% | n/a | n/a | n/a |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $894M | -8% | -1% | -2% | 30.6× | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $828M | -8% | +3% | 3% | n/a | n/a | n/a |
| CARsgen Therapeutics 2171.HK | Hong Kong | $825M | -54% | +68% | -170% | n/a | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $825M | -8% | +2% | 20% | n/a | -1.8% | +2.6% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $907M | -12% | -25% | 2% | n/a | 16.2% | -0.2% |
| Wanbangde Pharmaceutical 002082.SZ | China | $909M | -65% | -11% | -3% | n/a | -1.2% | -39.5% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $909M | -33% | -14% | -29% | n/a | n/a | n/a |
| Bide Pharmatech 688073.SS | China | $912M | +5% | +10% | 19% | 27.5× | 16.7% | +27.7% |
| Oric Pharmaceuticals ORIC | United States | $914M | 0% | n/a | n/a | n/a | n/a | n/a |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $808M | -7% | +8% | 10% | n/a | 10.7% | -1.4% |